Dementia, especially Alzheimer's disease, is a challenging condition that profoundly impacts both patients and their caregivers. As the number one cause of dementia, Alzheimer's disease leads to progressive cognitive decline, memory loss, and behavioral changes that can be difficult to manage. Recent research has focused on GLP-1 receptor agonists (GLP-1s), a class of drugs originally developed for diabetes treatment, which show potential neuroprotective effects in Alzheimer's disease. GLP-1s may help reduce inflammation and improve brain insulin signaling, which are critical factors in the progression of Alzheimer's dementia. Some clinical trials have investigated the effects of GLP-1s on cognitive function, with promising early findings suggesting improvements in memory and brain metabolism. These findings offer hope for delaying or preventing the onset of dementia symptoms through pharmacological intervention focused on brain health. Caregivers of individuals with dementia often face significant emotional and physical burdens, making disease prevention and improved treatment options critically important. By understanding emerging therapies like GLP-1s, both caregivers and patients can be more informed about potential future options. Additionally, lifestyle measures such as maintaining cardiovascular health, a balanced diet, mental stimulation, and physical activity remain essential components for preventing or slowing dementia progression. As research continues, it is important to follow developments in GLP-1 therapies and consult healthcare professionals for individualized advice. Overall, the evolving landscape of dementia treatment research underscores the vital importance of holistic brain health strategies combined with scientific innovation aimed at combating Alzheimer’s disease.